Endo Bids For Salix; Valeant May Be Thwarted Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo confirmed March 11 that it has offered to acquire the GI specialist for $175 per share, trumping Valeant’s $158 per share offer announced in February.
You may also be interested in...
Endo’s Next Chapter Will Be Led By CEO De Silva
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.